JP2015513083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513083A5 JP2015513083A5 JP2014558737A JP2014558737A JP2015513083A5 JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5 JP 2014558737 A JP2014558737 A JP 2014558737A JP 2014558737 A JP2014558737 A JP 2014558737A JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5
- Authority
- JP
- Japan
- Prior art keywords
- psma
- agent
- imaging
- adenocarcinoma
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602900P | 2012-02-24 | 2012-02-24 | |
| US61/602,900 | 2012-02-24 | ||
| PCT/US2013/000045 WO2013126147A2 (en) | 2012-02-24 | 2013-02-22 | Elevated psma identifies lethal prostate cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050913A Division JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513083A JP2015513083A (ja) | 2015-04-30 |
| JP2015513083A5 true JP2015513083A5 (https=) | 2016-03-31 |
| JP6501524B2 JP6501524B2 (ja) | 2019-04-17 |
Family
ID=49003541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558737A Expired - Fee Related JP6501524B2 (ja) | 2012-02-24 | 2013-02-22 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
| JP2019050913A Pending JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050913A Pending JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130225541A1 (https=) |
| EP (2) | EP2817629A4 (https=) |
| JP (2) | JP6501524B2 (https=) |
| CA (1) | CA2865282A1 (https=) |
| HK (1) | HK1205788A1 (https=) |
| WO (1) | WO2013126147A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013130177A1 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| AU2017348111B2 (en) * | 2016-10-27 | 2023-04-06 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| EP4597424A3 (en) | 2019-01-07 | 2025-10-29 | Exini Diagnostics AB | Systems and methods for platform agnostic whole body image segmentation |
| BR112021021011A2 (pt) | 2019-04-24 | 2021-12-14 | Exini Diagnostics Ab | Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| BR112022019335A2 (pt) | 2020-03-26 | 2022-11-29 | Marigdalia Kaleth Ramirez Fort | Método para determinar uma quantidade de energia a ser entregue para provocar um efeito final em uma entidade invasiva-alvo de um alvo em um hospedeiro, método para fornecer terapia a um alvo com o uso de um dispositivo inteligente, método para monitorar um paciente exposto a um carcinógeno conhecido em um evento de exposição, método para tratar adaptativamente um volume de células com irradiação eletromagnética, método para medir a dose absorvida de energia entregue por meio de um alvo dentro de um volume de células, método para permitir regulação ascendente de depravação de androgênio, método para otimizar a dose absorvida de irradiação eletromagnética entregue por meio de um alvo dentro de um volume de células, sistema de terapia para um apêndice de paciente e sistema de terapia para uma cavidade de paciente |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| CA3231578A1 (en) | 2021-10-08 | 2023-04-13 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE337011T1 (de) * | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| ATE408712T1 (de) * | 2003-01-10 | 2008-10-15 | Millennium Pharm Inc | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
| WO2005021709A2 (en) * | 2003-05-29 | 2005-03-10 | Diadexus, Inc. | Cln101 antibodies |
| JP2010507645A (ja) * | 2006-10-25 | 2010-03-11 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 前立腺癌を検出するための造影剤 |
| CA2700410C (en) * | 2007-10-03 | 2020-10-06 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| US20110189093A1 (en) * | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
| CN102308212A (zh) * | 2008-12-04 | 2012-01-04 | 加利福尼亚大学董事会 | 用于确定前列腺癌诊断和预后的材料和方法 |
| ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
| WO2010107909A2 (en) * | 2009-03-17 | 2010-09-23 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
-
2013
- 2013-02-22 US US13/773,857 patent/US20130225541A1/en not_active Abandoned
- 2013-02-22 WO PCT/US2013/000045 patent/WO2013126147A2/en not_active Ceased
- 2013-02-22 JP JP2014558737A patent/JP6501524B2/ja not_active Expired - Fee Related
- 2013-02-22 HK HK15106199.9A patent/HK1205788A1/xx unknown
- 2013-02-22 EP EP13752566.3A patent/EP2817629A4/en not_active Withdrawn
- 2013-02-22 EP EP16166503.9A patent/EP3064945A1/en not_active Withdrawn
- 2013-02-22 CA CA2865282A patent/CA2865282A1/en not_active Abandoned
-
2017
- 2017-05-15 US US15/595,533 patent/US20180088120A1/en not_active Abandoned
-
2019
- 2019-03-19 JP JP2019050913A patent/JP2019144254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513083A5 (https=) | ||
| Alam et al. | Emerging intraoperative imaging modalities to improve surgical precision | |
| Giesel et al. | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | |
| Rowe et al. | PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges | |
| Kanoun et al. | Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma | |
| Servagi-Vernat et al. | A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy | |
| Zangheri et al. | PET/CT and breast cancer | |
| Giganti et al. | Gastric cancer and imaging biomarkers: part 1–a critical review of DW-MRI and CE-MDCT findings | |
| JP6501524B2 (ja) | Ｐｓｍａ上昇により致死性前立腺癌が同定される | |
| Udovicich et al. | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends | |
| Bailey et al. | Performance of 68Ga-PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence | |
| Delouya et al. | 18F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer | |
| Tang et al. | Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5, 7-Diethyl-2-(4-(2-[18F] fluoroethoxy) phenyl) pyrazolo [1, 5-a] pyrimidin-3-yl)-N, N-diethylacetamide ([18F] VUIIS1008) in glioma | |
| Basu et al. | Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment | |
| Abgral et al. | Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer | |
| Kurihara et al. | Molecular imaging using PET for breast cancer | |
| Zhou et al. | Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer | |
| Estorch et al. | Future challenges of multimodality imaging | |
| Lewis et al. | [18f] fluoroethyltyrosine-induced cerenkov luminescence improves image-guided surgical resection of glioma | |
| Wáng et al. | Molecular imaging: from bench to clinic | |
| Zhao et al. | Somatostatin receptor imaging with [68Ga] Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma | |
| Li et al. | Noninvasive detection of cancer spread to lymph nodes: A review of molecular imaging principles and protocols | |
| Bouchelouche et al. | Advances in imaging modalities in prostate cancer | |
| JP2015508903A5 (https=) | ||
| Luo et al. | Harnessing the power of molecular imaging for drug discovery and development |